• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectar Biosciences, Inc. - Common Stock (NQ: CLRB )

    0.2350 -0.0030 (-1.26%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,193,614
    Open 0.2400
    Bid (Size) 0.2310 (31)
    Ask (Size) 0.2380 (110)
    Prev. Close 0.2380
    Today's Range 0.2300 - 0.2495
    52wk Range 0.2240 - 4.430
    Shares Outstanding 40,566,534
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session
    Via Benzinga
    Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
    Via Benzinga
    Exposures Fossil Fuels

    Performance

    YTD
    -91.78%
    -91.78%
    1 Month
    -85.13%
    -85.13%
    3 Month
    -88.19%
    -88.19%
    6 Month
    -91.78%
    -91.78%
    1 Year
    -91.00%
    -91.00%

    More News

    Read More
    Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
    Via Benzinga
    Exposures Product Safety
    Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Earnings Preview For Cellectar Biosciences
    Via Benzinga
    Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 18, 2024
    Via Benzinga
    Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
    From Cellectar Biosciences, Inc.
    Via GlobeNewswire
    Gold Moves Higher; Coca-Cola Increases FY24 Forecast
    Via Benzinga
    Crude Oil Down 2%; GE Aerospace Earnings Top Views
    Via Benzinga
    Exposures Fossil Fuels
    Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
    Via Benzinga
    Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024
    Via InvestorPlace
    Hedgeye Warns That Reddit (RDDT) Stock Will Fall 50%
    Via InvestorPlace
    Why Is Gamida Cell (GMDA) Stock Down 82% Today?
    Via InvestorPlace
    CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023
    Via InvestorPlace
    Earnings Scheduled For March 27, 2024
    Via Benzinga
    Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why
    Via Benzinga
    Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?
    Via Benzinga
    Wells Fargo Is Warming Up to Enphase Energy (ENPH) Stock
    Via InvestorPlace
    Why Is Spirit AeroSystems (SPR) Stock Down 14% Today?
    Via InvestorPlace
    Why Is LumiraDx (LMDX) Stock Down 13% Today?
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.